ClinicalTrials.Veeva

Menu

Continuous Glucose Monitorization in Hospitalized Patients With COVID-19

I

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Status

Enrolling

Conditions

Diabetes Mellitus
Covid19

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

DM2 is a major comorbidity of COVID-19. It has been observed that subjects with DM2 require more medical interventions, have a significantly higher mortality (7.8% versus 2.7%) and injuries of multiple organs that the individuals not diabetics.

In situations of glycemic variability, phenomena of oxidative stress and activation of protein kinase C can be initiated , through the release of pro-inflammatory cytosines , which could induce microvascular damage .Patients with diabetes and COVID-19 were shown to be more likely to develop serious or critical illness with more complications, and to have higher incidence rates of antibiotic therapy, non-invasive and invasive mechanical ventilation, and death (11.1% vs. 4.1%).

Enrollment

120 estimated patients

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Confirmed COVID-19 pneumonia
  • Diabetes mellitus

Exclusion criteria

  • Less than 3 days of hospital care

Trial contacts and locations

1

Loading...

Central trial contact

ALFONSO GULIAS HERRERO; ALHELY GAYTAN SANTILLAN

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems